PROGRAM PLANNING COMMITTEE

William C. Eckelman
David M. Goldenberg (Chairman)
Edgar Haber
Thomas Hoffman
Steven M. Larson
Stanley E. Order
Howard Sands
Mette Strand

PROGRAM

Introduction to the Second Conference on Radioimmunodetection and Radioimmunotherapy of Cancer.
David M. Goldenberg .......................................................... 778s

SESSION I

Radiochemistry of Antibodies

Chairperson: William C. Eckelman

Development of Radiochemically Pure Antibodies.
W. C. Eckelman ................................................................. 780s

Improving the Tumor Retention of Radioiodinated Antibody: Aryl Carbohydrate Adducts.
Seham A. Ali, Stephen D. Warren, Karen Y. Richter, Christopher C. Badger, Janet F. Eary, Oliver W. Press,
Kenneth A. Krohn, Irwin D. Bernstein, and Wil B. Nelp .......................................................... 783s

Stable Bifunctional Chelates of Metals Used in Radiotherapy.
Min K. Moi, Sally J. DeNardo, and Claude F. Meares .......................................................... 789s

Preclinical Evaluation of an “Instant” 99mTc-labeling Kit for Antibody Imaging.
Hans J. Hansen, Anastasia L. Jones, Robert M. Sharkey, Ruth Grebenau, Nancy Blazejewski, Arthur Kunz,
Michael J. Buckley, Edward S. Newman, Frank Ostella, and David M. Goldenberg ......................... 794s

99mTc Labeling of Proteins: Initial Evaluation of a Novel Diaminedithiol Bifunctional Chelating Agent.
Kwanena E. Baidoo, Ursula Scheffel, and Susan Z. Lever .......................................................... 799s

Disulfide Bond-targeted Radiolabeling: Tumor Specificity of a Streptavidin-biotinylated Monoclonal Antibody Complex.
Renato B. del Rosario and Richard L. Wahl .......................................................... 804s

SESSION II

Experimental Studies of Radioimmunodetection

Chairpersons: Howard Sands and Jeffrey Schlom

Experimental Studies of Radioimmunodetection of Cancer: An Overview.
Howard Sands ................................................................. 809s

Physiological Barriers to Delivery of Monoclonal Antibodies and Other Macromolecules in Tumors.
Rakesh K. Jain ................................................................. 814s

Innovations That Influence the Pharmacology of Monoclonal Antibody Guided Tumor Targeting.
Jeffrey Schlom, Patricia Horan Hand, John W. Greiner, David Colcher, Shashi Shrivastav, Jorge A. Carrasquillo,
James C. Reynolds, Steven M. Larson, and Andrew Raubitschek .................................................. 820s

Comparison of Tumor Targeting in Nude Mice by Murine Monoclonal Antibodies Directed against Different Human Colorectal Cancer Antigens.
Ostella, Hans J. Hansen, and David M. Goldenberg .......................................................... 828s

Pharmacokinetics of 99mTc-Metallothionein-B72.3 and Its F(ab’), Fragment.
Beverly A. Brown, Cynthia B. Dearborn, Cynthia A. Drozynski, and Howard Sands ......................... 835s

Mechanisms of Tissue Uptake and Metabolism of Radiolabeled Antibody—Role of Antigen:Antibody Complex Formation.
J. David Beatty, Barbara G. Beatty, Margaret O’Conner-Tressel, Tulan Do, and Raymond J. Paxton ....... 840s
Mechanism of Decreasing Liver Uptake of \(^{111}\)In-labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody by Specific Antibody Pretreatment in Tumor Bearing Mice.

Barbara G. Beatty, Margaret O’Conner-Tressel, Tulan Do, Raymond J. Paxton, and J. David Beatty

Uptake and Metabolism of \(^{111}\)In-labeled Monoclonal Antibody B6.2 by the Rat Liver.

Peter L. Jones, Beverly A. Brown, and Howard Sands

Site-specifically Radiiodinated Antibody for Targeting Tumors.

Douglas W. Rea, Michiel E. Ullee, Benjamin A. Belinka, Jr., Daniel J. Coughlin, and Vernom L. Alvarez

Radiolocalization of Monoclonal Antibodies in Hepatic Metastases from Human Colon Cancer in Congenitally Athymic Mice.

Kazuhiko Yoshida, Michel Rivoire, Chaitanya Divgi, Sydney Welt, Alfred M. Cohen, and Elin R. Sigurdson

Monoclonal Antibody Targeting of Human Non-Small Cell Carcinoma of the Lung.

Rhona Stein, Robert M. Sharkey, and David M. Goldenberg

Carcinoembryonic Antigen and \(\alpha\)-Fetoprotein Expression and Monoclonal Antibody Targeting in a Human Hepatoma/Nude Mouse Model.

Zhifu F. Wang, Rhona Stein, Robert M. Sharkey, and David M. Goldenberg

Comparative Pharmacokinetics of a Murine Monoclonal Antibody to a Rat Colon Tumor in Rats and Nude Mice.

Jorge Laborda, Jean-Yves Douillard, Elaine F. Lizzo, and Thomas Hoffman

Radioimmunodetection of Hepatic Metastases from Human Colon Cancer in Nude Mice with a Gamma-detecting Probe.

Michel Rivoire, Kazuhiko Yoshida, Chaitanya Divgi, Sydney Welt, Alfred Cohen, and Elin R. Sigurdson

Patterns of Antigen Distribution in Human Carcinomas.

M. Jules Mattes, Pierre P. Major, David M. Goldenberg, Arnold S. Dion, Robert V. P. Hutter, and Kenneth M. Klein

Use of Whole-Body Autoradiography in Cancer Targeting with Radiolabeled Antibodies.

Irwin Fand, Robert M. Sharkey, and David M. Goldenberg

---

SESSION III

Clinical Studies of Radioimmunodetection

Chairpersons: Steven M. Larson and Abass Alavi


Steven M. Larson

Tumor Immunoscintigraphy by Means of Radiolabeled Monoclonal Antibodies: Multicenter Studies of the Italian National Research Council—Special Project “Biomedical Engineering”.

Antonio G. Siccardi

Radioimaging of Melanoma Using \(^{99m}\)Tc-labeled Fab Fragment Reactive with a High Molecular Weight Melanoma Antigen.

Lamk M. Lamki, Alexander A. Zukiwski, L. Joy Shanken, Sewa S. Legha, Robert S. Benjamin, Carl E. Plager, Darrell F. Salk, Robert W. Schroff, and James L. Murray

Clinical Studies of Cancer Radioimmunodetection with Carcinoembryonic Antigen Monoclonal Antibody Fragments Labeled with \(^{125}\)I or \(^{99m}\)Tc.

David M. Goldenberg, Hildegard Goldenberg, Robert M. Sharkey, Edith Higginbotham-Ford, Robert E. Lee, Lawrence C. Swayne, Karen A. Burger, Diane Tsai, Jo Ann Horowitz, Thomas C. Hall, Carl M. Pinsky, and Hans J. Hansen

Presurgical Imaging with Indium-labeled Anti-Carcinoembryonic Antigen for Colon Cancer Staging.

J. David Beatty, Lawrence E. Williams, David Yamauchi, Blaine A. Morton, L. Robert Hill, Barbara G. Beatty, Raymond J. Paxton, Bruce Merchand, and John E. Shively

Breast Tumor Radioimmunodetection with a \(^{111}\)In-labeled Monoclonal Antibody (MAS) against a Mucin-like Antigen.

Pierre P. Major, Arnold S. Dion, Charlene J. Williams, M. Jules Mattes, Taqui Wang, and Leonard Rosenhall

Human Biodistribution of \(^{111}\)In-labeled B72.3 Monoclonal Antibody.

Steven J. Harwood, Robert G. Carroll, William B. Webster, Linda M. Zangara, David L. Laven, Michele A. Morrisey, and Barbara J. Sinni

Immunolymphoscintigraphy and Immunoscintigraphy of Ovarian and Fallopian Tube Cancer Using F(ab’\(^{1}\)) Fragments of Monoclonal Antibody OC 125.

Pentti Lehtovirta, Kalevi J. A. Kairemo, Kristian Liewendahl, and Markku Seppälä

Lymphoscintigraphy in Melanoma: Initial Evaluation of a Low Protein Dose Monoclonal Antibody Cocktail.

Richard L. Wahl, Monica Liebert, John Headington, Barry S. Wilson, Barry L. Shulkin, Jon W. Johnson, Shirley Mallette, Ronald B. Natale, William Coon, Mary East, Robertson Davenport, M. B. Brown, John T. Niederhuber, and Neil A. Swanson

Immunolymphoscintigraphy with \(^{99m}\)Tc-labeled Monoclonal Antibody (BW 431/26) Reacting with Carcinoembryonic Antigen in Breast Cancer.

Kalevi J. A. Kairemo
Radioimmunodetection in Rhabdo- and Leiomyosarcoma with $^{111}$In-Anti-Myosin Monoclonal Antibody Complex.
André Planting, Jaap Verweij, Peter Cox, Mike Pillay, and Gerrit Stoter ................................................................. 955s

Detection of Thrombophlebitis with $^{111}$In-labeled Anti-Fibrin Antibody: Preliminary Results.
Abass Alavi, Naresh Gupta, Harold J. Palevsky, Mark A. Kelley, Allison D. Jatlow, Ann A. Byar, and Harvey J. Berger ................................................................. 958s

SESSION IV

Prospects for Therapy, I: Experimental

Chairperson: Mette Strand

David A. Scheinberg and Mette Strand ................................................................. 962s

Biological Considerations for Radioimmunotherapy.
Robert M. Sharkey, Rosalyn D. Blumenthal, Hans J. Hansen, and David M. Goldenberg ................................................................. 964s

Current Status of Animal Radioimmunotherapy.
Barry W. Wessels ................................................................. 970s

Targeting and Therapy of Human Glioma Xenografts in Vivo Utilizing Radiolabeled Antibodies.
Jeffery A. Williams, Barry W. Wessels, James A. Edwards, Kenneth A. Kopher, Philip M. Wanek, Moody D. Wharam, Stanley E. Order, and Jerry L. Klein ................................................................. 974s

Imaging and Therapy of Small Cell Carcinoma Xenografts Using $^{131}$I-labeled Monoclonal Antibody SWA11.
Alan Smith, Peter Groscurth, Robert Wabeil, Gerrit Westera, and Rolf A. Stahel ................................................................. 980s

Radioimmunotherapy of Peritoneal Human Colon Cancer Xenografts with Site-specifically Modified $^{212}$Bi-labeled Antibody.
R. Bruce Simonson, Michele E. Ultee, Jo A. Hauler, and Vernon L. Alvarez ................................................................. 985s

Radioimmunotherapy of Human Colon Carcinomatosis Xenograft with $^{90}$Y-ZCE025 Monoclonal Antibody: Toxicity and Tumor Phenotype Studies.
Jose M. Esteban, David M. Hyams, Barbara G. Beatty, Bruce Merchant, and J. David Beatty ................................................................. 989s

Comparative Binding and Preclinical Localization and Therapy Studies with Radiolabeled Human Chimeric and Murine 17-1A Monoclonal Antibodies.
Donald J. Buchsbaum, Pamela G. Brubaker, David E. Hanna, Arthur A. Glatfelter, Valeri H. Terry, Dianne M. Guitbault, and Zenon Stepleski ................................................................. 993s

Tumor Spheroid Model for the Biologically Targeted Radiotherapy of Neuroblastoma Micrometastases.
K. A. Walker, R. Mairs, T. Murray, T. E. Hilditch, T. E. Wheldon, A. Gregor, and J. M. Hann ................................................................. 1000s

Use of Hematopoietic Growth Factors to Control Myelosuppression Caused by Radioimmunotherapy.
R. D. Blumenthal, R. M. Sharkey, L. M. Quinn, and D. M. Goldenberg ................................................................. 1003s

Role of Bone Marrow Transplantation in $^{90}$Y Antibody Therapy of Colon Cancer Xenografts in Nude Mice.
Blaine A. Morton, Barbara G. Beatty, Angeles P. Mison, Philip M. Wanek, and J. David Beatty ................................................................. 1008s

SESSION V

Prospects for Therapy, II: Clinical

Chairperson: Stanley E. Order

Radiolabeled Antibodies: Results and Potential in Cancer Therapy.
S. E. Order, A. M. Sleeper, G. B. Stillwagon, J. L. Klein, and P. K. Leichner ................................................................. 1011s

Fractionated Radioimmunotherapy of B-Cell Malignancies with $^{131}$I-Lym-1.
Gerald L. DeNardo, Sally J. DeNardo, Lois F. O’Grady, Norman B. Levy, Gregory P. Adams, and Stanley L. Mills ................................................................. 1014s

High Dose Radiolabeled Antibody Therapy of Lymphoma.

Radioimmunotherapy of Human B-Cell Lymphoma with $^{90}$Y-conjugated Antiidiotype Monoclonal Antibody.

Estimation of Monoclonal Antibody-associated $^{90}$Y Activity Needed to Achieve Certain Tumor Radiation Doses in Colorectal Cancer Patients.
Lawrence E. Williams, Barbara G. Beatty, J. David Beatty, Jeffrey Y. C. Wong, Raymond J. Paxton, and John E. Shively ................................................................. 1029s

Intraperitoneal Immunocoujugates.
Thomas W. Griffin, Jeffrey Collins, Faran Bokhari, Mark Stochl, A. Bertrand Brill, Tsunao Ito, Georgette Emond, and Howard Sands ................................................................. 1031s
Tumor, Red Marrow, and Organ Dosimetry for $^{131}I$-labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody. 

Jeffry A. Siegel, David A. Pawlyk, Robert E. Lee, Norma L. Sasso, Jo Ann Horowitz, Robert M. Sharkey, and David M. Goldenberg .................................................. 1039s

Dosimetric Model for Antibody Targeted Radionuclide Therapy of Tumor Cells in Cerebrospinal Fluid.

W. T. Millar and A. Barrett .................................................. 1043s

SESSION VI

Host Responses and Complications

Chairperson: Thomas Hoffman

Anticipating, Recognizing, and Preventing Hazards Associated with in Vivo Use of Monoclonal Antibodies: Special Considerations Related to Human Anti-Mouse Antibodies.

Thomas Hoffman .................................................. 1049s


Herve M. Bloutiere, J. Y. Douillard, H. Koprowski, and Z. Steplewski .................................................. 1051s

Human Immune Response to Anti-Carcinoembryonic Antigen Murine Monoclonal Antibodies.

Michele J. Losman, Robert L. DeJager, Marc Monestier, Robert M. Sharkey, and David M. Goldenberg .............. 1055s

Author Index .................................................. 1059s

COVER LEGEND

The publication of the first conference held on the subject of cancer imaging and therapy with radiolabeled antibodies appeared as a supplement to the August 1980 issue of Cancer Research and has served as a frequently cited reference for the past 10 years.

Pictured are five of the scientists who made critical contributions to the development of radioimmunodetection and radioimmunotherapy. Phil Gold (far left), codiscoverer of carcinoembryonic antigen, which has served as the prototype cancer marker and target for labeled antibodies, is currently Physician-in-Chief, Montreal General Hospital, Montreal, Canada. David Pressman (second from left), deceased, is credited with having made the early and seminal observations of organ and cancer targeting with antibodies against rodent tumors. David M. Goldenberg (center), who is President of the Center for Molecular Medicine and Immunology, Newark, New Jersey, organized the first and second conferences and provided the first demonstration in animals and humans of cancer imaging with radiolabeled antibodies against carcinoembryonic antigen, as well as a number of other cancer markers. William F. Bale (second from right), deceased, also was an early pioneer of animal studies of tumor localization with radiolabeled antibodies and pursued fibrin clot imaging and tumor therapy with radiolabeled anti-fibrin antibodies. Stanley E. Order (far right), who was one of the first proponents and innovators of radioimmunotherapy, is currently Professor and Director of Radiation Oncology, Johns Hopkins Cancer Center, Baltimore, Maryland. This photograph was made at the UICC Workshop on Radioimmunodetection of Cancer, Lexington, Kentucky, July 19–21, 1979.
Cancer Research

50 (3 Supplement)

Cancer Res 1990;50:1017s-834s.

Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/50/3_Supplement.citation

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.